Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics

Adverum Biotechnologies, Inc. (ADVM): $11.73

0.24 (-2.01%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ADVM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#103 of 360

in industry

ADVM Price/Volume Stats

Current price $11.73 52-week high $29.70
Prev. close $11.97 52-week low $7.10
Day low $11.52 Volume 151,300
Day high $12.24 Avg. volume 250,167
50-day MA $17.33 Dividend yield N/A
200-day MA $14.04 Market Cap 243.46M

ADVM Stock Price Chart Interactive Chart >


Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and saf

Yahoo | December 7, 2023

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m.

Yahoo | November 28, 2023

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - - Cash runway projected into 2

Yahoo | November 9, 2023

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience

Yahoo | November 6, 2023

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden - - 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 - - Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection - - Ixo-vec continues to be generally wel

Yahoo | November 4, 2023

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo -32.20%
3-mo 37.82%
6-mo 33.30%
1-year 39.64%
3-year -87.21%
5-year -79.38%
YTD 55.82%
2023 29.91%
2022 -67.07%
2021 -83.76%
2020 -5.90%
2019 265.71%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!